Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 16.7% during mid-day trading on Friday . The company traded as low as C$0.08 and last traded at C$0.08. 405,500 shares were traded during trading, an increase of 4% from the average session volume of 389,087 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$11.66 million, a P/E ratio of -2.33 and a beta of 0.20. The stock has a fifty day moving average of C$0.12 and a 200-day moving average of C$0.13.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Energy Stocks to Gain Exposure to the Carbon Capture Boom
- How to Use the MarketBeat Dividend Calculator
- AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple
- 3 Small Caps With Big Return Potential
- The Real Reason Ford Stock Is Rallying—Can It Keep Going?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
